N+1 Singer Reiterated Vernalis PLC (LON:VER) As Hold; Has Target Price per Share Of GBX 46.00

Vernalis PLC (LON:VER) Rating

Analysts at N+1 Singer have GBX 46.00 target price per share on Vernalis PLC (LON:VER). N+1 Singer’s target price per share would indicate a potential upside of 12.52% from the company’s close price. The rating was revealed to investors in a research note on Thursday morning.

Out of 5 analysts covering Vernalis PLC (LON:VER), 4 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 80% are positive. GBX 138 is the highest target while GBX 46 is the lowest. The GBX 79 average target is 93.87% above today’s (GBX 40.75) stock price. Vernalis PLC has been the topic of 22 analyst reports since October 2, 2015 according to StockzIntelligence Inc. N+1 Singer maintained the stock on September 29 with “Hold” rating. Shore Capital maintained it with “House Stock” rating and GBX 56 target price in a February 5 report. Cantor Fitzgerald maintained the shares of VER in a report on August 4 with “Buy” rating. Lastly, Stifel Nicolaus maintained the stock with “Buy” rating in a July 8 report.

About 717,663 shares traded hands or 316.03% up from the average. Vernalis plc (LON:VER) has declined 27.35% since February 29, 2016 and is downtrending. It has underperformed by 38.60% the S&P500.

Analysts await Vereit Inc (NYSE:VER) to report earnings on November, 3. They expect $0.18 earnings per share, down 14.29% or $0.03 from last year’s $0.21 per share. VER’s profit will be $172.71 million for 14.40 P/E if the $0.18 EPS becomes a reality. After $0.19 actual earnings per share reported by Vereit Inc for the previous quarter, Wall Street now forecasts -5.26% negative EPS growth.

Vernalis plc is a commercial-stage pharmaceutical holding company. The company has a market cap of 213.47 million GBP. The Firm is engaged in the research, development and commercialization of pharmaceutical products for a range of medical disorders. It currently has negative earnings. The Firm has two marketed products: Tuzistra XR in the United States prescription cough cold market, and frovatriptan, an acute treatment for migraine.

According to Zacks Investment Research, “VEREIT, Inc. is a real estate operating company. The Company owns and manages a diversified portfolio of retail, restaurant, office and industrial real estate assets. VEREIT, Inc., formerly known as American Realty Capital Properties Inc., is based in Phoenix, United States.”

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment